Skip to content
New: Acetyl-L-Carnitine Benefits: The Real Evidence

Supplements

Why Do People Stop Taking NMN?

MitoHacker·Updated July 6, 2026·2 min read
Share:

Community Consensus

Community Consensus

Reader sentiment on the compounds this article compares. Votes count toward each compound's own tally.

  1. NMN
    2.2k votes · 75%👍
  2. NAD+
    1.3k votes · 79%👍

Reader sentiment only. Not medical advice, not a recommendation, and not a measure of evidence quality.

Quick answer

People stop taking NMN mostly because they don't feel any effect. Its benefits (raising NAD+, supporting cellular aging) are invisible and long-term, so it seems like 'nothing is happening.' Other common reasons: the ongoing cost, NMN's contested US regulatory status, expectations set too high by longevity marketing, and switching to NR or to exercise. Pausing doesn't forfeit a proven benefit.

Key takeaways

  • The top reason is feeling nothing; NMN's effects are invisible and long-term, not day-to-day.
  • NMN reliably raises NAD+ biochemically, but felt benefits in healthy people are unproven.
  • Cost is an ongoing, open-ended expense for a benefit you can't perceive.
  • NMN's US supplement status has been contested by the FDA, creating uncertainty.
  • Some switch to NR (more data, no regulatory cloud) or to exercise (free NAD+ booster).

Why this question comes up

NMN was one of the most hyped longevity supplements of the last decade. So it’s telling that “why I stopped taking NMN” has become such a common search. People start NMN expecting to feel something, and when they don’t, they reassess. Here are the honest, real-world reasons people quit, separated from the hype on both sides.

1. They didn’t feel anything

This is the big one. NMN’s proposed benefits (raising NAD+, supporting metabolism and cellular aging) are mostly invisible and long-term. There’s rarely a noticeable day-to-day effect, so people conclude “it’s not doing anything” and stop. In reality, NMN reliably raises NAD+ at the biochemical level. The honest gap is that raising NAD+ hasn’t been proven to translate into felt benefits in healthy people. No sensation isn’t the same as no effect. But it’s understandably unsatisfying.

2. The cost adds up

Quality NMN isn’t cheap, and it’s an open-ended monthly expense for a benefit you can’t perceive. When budgets tighten, an invisible longevity bet is an easy line item to cut.

3. The regulatory cloud

NMN’s status as a US dietary supplement has been contested by the FDA, creating uncertainty about availability and legality. Some people stop simply because the shifting legal picture makes them uneasy or disrupts their supply. (Details in the NAD+, NR and NMN guide.)

4. The evidence didn’t hold up to their expectations

Longevity marketing implied dramatic anti-aging results. The actual human trials are early and modest. NMN raises NAD+ and shows some specific effects (e.g. insulin sensitivity in certain groups), but nothing resembling the “reverse aging” framing. People who read the real research often downgrade their expectations, and some quit.

5. They switched to NR (or to exercise)

Some don’t quit NAD+ boosting entirely. They switch to NR, which has more human data and no regulatory cloud, or they refocus on the free NAD+ booster with the strongest evidence: exercise.

Should you stop?

If you’re taking NMN, feel nothing, and the cost stings, that’s a rational reason to reassess, and you’re not missing a proven benefit by pausing. If you’re comfortable with a long-term, evidence-plausible-but-unproven bet and the cost is trivial to you, continuing is also reasonable. Just calibrate expectations to the actual science, not the marketing.

Educational information only, not medical advice. Talk to a clinician about your specific situation.

Frequently asked questions

Why do people stop taking NMN?

The most common reason is that they don't feel anything. NMN's proposed benefits are largely invisible and long-term, so it seems ineffective. Cost, NMN's contested US regulatory status, over-hyped expectations, and switching to NR or exercise are the other main reasons.

Does NMN actually do anything if I don't feel it?

NMN reliably raises NAD+ at the biochemical level, so 'feeling nothing' isn't the same as 'no effect.' The honest gap is that raising NAD+ has not been proven to produce noticeable benefits in healthy people, so there's often nothing to feel.

Is it bad to stop taking NMN?

No. There's no proven felt benefit you forfeit by pausing, and no known withdrawal effect. If you feel nothing and the cost stings, reassessing is rational. If the cost is trivial and you're comfortable with an unproven long-term bet, continuing is also reasonable.

Should I switch from NMN to NR?

Some people do. NR has more human clinical data and no contested regulatory status, so it's a reasonable alternative if NMN's legal uncertainty bothers you. Both raise NAD+; neither has proven felt benefits in healthy people.

References

  1. 1.Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547.
  2. 2.Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
  3. 3.Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.

Keep reading

Supplements

Acetyl-L-Carnitine Benefits: The Real Evidence

Acetyl-L-carnitine, sold as ALCAR, is L-carnitine with an acetyl group attached, and that single modification is why it exists as a separate product: it crosses the blood-brain barrier more readily than plain L-carnitine. The strongest human evidence is in peripheral neuropathy and depressive symptoms. Two 52-week randomised placebo-controlled trials in 1,257 patients with diabetic neuropathy found improved sural nerve fibre numbers, regenerating fibre clusters, pain and vibratory perception at 1,000 mg three times daily, with more benefit in patients treated earlier. A meta-analysis of 12 trials in 791 participants found reduced depressive symptoms, comparable to standard antidepressants with fewer side effects. It is weakest at the two things it is most often sold for. The dementia trials did not deliver despite a strong acetylcholine mechanism, and a Cochrane review found insufficient evidence to recommend it. Most importantly, in 409 women receiving taxane chemotherapy, 3,000 mg/day of ALCAR made neuropathy significantly worse than placebo, and the effect was still present at 104 weeks. That result means ALCAR should be treated as a compound with specific indications, not a general nerve or brain supplement.

Read →

Supplements

L-Carnitine Side Effects: What Actually Happens

At ordinary supplement doses most people tolerate L-carnitine well. The side effects that do appear are dose-dependent: nausea, abdominal cramping and diarrhoea, plus a fishy body, breath and urine odour that surprises people because it is not an allergy or a bad batch. Gut bacteria convert unabsorbed carnitine into trimethylamine, which smells like rotting fish and leaves the body through sweat and breath, so a shower does not fix it. It is dose-related and fully reverses on stopping. A published risk assessment put the observed safe level at 2,000 mg per day. Four situations deserve real caution rather than a shrug: an existing seizure disorder, thyroid treatment, warfarin, and impaired kidney function. L-carnitine acts as a peripheral antagonist of thyroid hormone, which is why it works against levothyroxine treatment. One question is genuinely unresolved: gut bacteria convert carnitine to TMAO, which accelerated atherosclerosis in mice, while pooled human trials in cardiac patients found lower mortality. Both findings stand. Unusually for a supplement, the certificate of analysis that matters most here confirms isomeric identity rather than potency, because the D-isomer competitively interferes with L-carnitine transport.

Read →

Supplements

How Much Alpha-Lipoic Acid Per Day, and When to Take It

The reference figure is 600 mg per day, and it comes from SYDNEY 2, a trial that compared 600, 1,200 and 1,800 mg of oral alpha-lipoic acid head to head. All three doses improved symptom scores by almost exactly the same amount, roughly 48 to 52 percent against 32 percent on placebo, while nausea, vomiting and vertigo rose steadily with dose. The authors concluded 600 mg once daily gave the best risk-to-benefit ratio, which is why nearly every capsule sold holds that amount. On timing, take it on an empty stomach, about 30 minutes before a meal or two hours after: food both delays and reduces absorption, and alpha-lipoic acid already starts from only about 30 percent absolute bioavailability because the liver extracts most of a dose on first pass. The hour of day matters far less than being fasted, which is the real reason bedtime dosing is popular. Two caveats matter. Those trials studied people with diabetic polyneuropathy, so applying the number to general wellness use is an extrapolation, and the four-year NATHAN 1 trial at 600 mg daily missed its primary endpoint.

Read →